Clinical Trial Update: Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing aclidinium bromide 400 µg to placebo and to tiotropium in patients with stable moderate-to-severe chronic obstructive pulmonary disease;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Spiriva (tiotropium)
• TUDORZA PRESSAIR (ACLIDINIUM BROMIDE)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2013-05-22